SCHEMBL5496286

SCHEMBL5496286

NS(=O)(=O)N1CCN(c2ccc(-c3ccc(F)cc3)cc2)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.61
MAPT P10636 2/20 0.55
LMNA P02545 3/20 0.55
TDP1 Q9NUW8 2/20 0.55
MAPK1 P28482 2/20 0.55
HTT P42858 2/20 0.55
GFER P55789 1/20 0.55
HPGD P15428 1/20 0.54
POLB P06746 3/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
HSD11B1 P28845 1/20 0.51
CA12 O43570 3/20 0.50
CA1 P00915 3/20 0.50
CA2 P00918 3/20 0.50
CA9 Q16790 3/20 0.50
TSHR P16473 1/20 0.49
SLC6A7 Q99884 1/20 0.49
USP30 Q70CQ3 1/20 0.48
PKM P14618 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2968565 0.95 ALDH1A1 (0.67) ALDH1A1MAPTLMNATDP1MAPK1
SCHEMBL31605436 0.80 ALDH1A1 (0.67) ALDH1A1MAPTLMNATDP1MAPK1
SCHEMBL2103149 0.79 ALDH1A1 (0.65) ALDH1A1MAPTLMNATDP1MAPK1
SCHEMBL941084 0.79 ALDH1A1 (0.65) ALDH1A1MAPTLMNATDP1MAPK1
SCHEMBL10373626 0.77 MAPT (0.77) ALDH1A1MAPTLMNATDP1MAPK1
SCHEMBL4671150 0.77 MEN1 (0.65) ALDH1A1MAPTLMNAHTTHPGD
SCHEMBL13591281 0.77 AKR1C3 (0.47) ALDH1A1MAPTLMNAHPGDPOLB
SCHEMBL13591219 0.77 MEN1 (0.69) ALDH1A1MAPTLMNAMAPK1MEN1
SCHEMBL6242244 0.76 CA2 (0.54) HTTHSD11B1CA12CA1CA2
SCHEMBL2959258 0.76 ALDH1A1 (0.57) ALDH1A1MAPTLMNAMAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1750712-A2 MEDICAMENTS CONTAINING N-SULFAMOYL-N'-ARYLPIPERAZINES FOR THE PROPHYLAXIS OR TREATMENT OF OBESITY AND RELATED CONDITIONS Solvay Pharmaceuticals GmbH (DE) 2007-02-14 EP disclosed
WO-2005110413-A2 MEDICAMENTS CONTAINING N-SULFAMOYL-N'-ARYLPIPERAZINES FOR THE PROPHYLAXIS OR TREATMENT OF OBESITY AND RELATED CONDITIONS SOLVAY PHARMACEUTICALS GMBH (DE) 2005-11-24 WO disclosed
US-20050261292-A1 Pharmaceutical composition containing N-sulfamoyl-N'-arylpiperazines for the treatment or inhibition of obesity and related conditions SOLVAY PHARMACEUTICALS GMBH (DE) 2005-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261292-A1 Pharmaceutical composition containing N-sulfamoyl-N'-arylpiperazines for the treatment or inhibition of obesity and related conditions GPR119, FABP4, SULT2A1 ALDH1A1 265/4885MAPT 3810/4885LMNA 4000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.